Antibody-drug conjugates and uses thereof
AssigneeImmunomedics, Inc.
InventorsDavid M. Goldenberg, Serengulam V. Govindan
Life of this patent
Estimating the term…
Abstract
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
Claims17
A method of treating an endometrial cancer comprising administering to a human patient with endometrial cancer an immunoconjugate sacituzumab govitecan (IMMU-132), wherein the immunoconjugate is administered to the human patient on Day 1 and Day 8 of a 21-day cycle.
A method of treating a metastatic endometrial cancer comprising administering to a human patient with metastatic endometrial cancer an immunoconjugate sacituzumab govitecan (IMMU-132) at a dosage between 8 and 10 mg/kg,
- wherein the immunoconjugate dosage is administered to the human patient on Day 1 and Day 8 of a 21-day cycle, and
- wherein the human patient had relapsed after or refractory to at least one prior therapy.
Dependencies are inferred from the claim text.